Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsCash from RestructuringChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Sales and DivestituresNet Cash FlowNet IncomeNon-Current DebtOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Cash from Financing Activities: 2019-2025

Historic Cash from Financing Activities for Legend Biotech (LEGN) over the last 7 years, with Sep 2025 value amounting to $670,000.

  • Legend Biotech's Cash from Financing Activities fell 84.22% to $670,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $14,000, marking a year-over-year decrease of 99.80%. This contributed to the annual value of $5.7 million for FY2024, which is 99.28% down from last year.
  • Per Legend Biotech's latest filing, its Cash from Financing Activities stood at $670,000 for Q3 2025, which was up 167.68% from -$990,000 recorded in Q2 2025.
  • Over the past 5 years, Legend Biotech's Cash from Financing Activities peaked at $790.0 million during Q2 2023, and registered a low of -$990,000 during Q2 2025.
  • Over the past 3 years, Legend Biotech's median Cash from Financing Activities value was $831,000 (recorded in 2024), while the average stood at $72.5 million.
  • Data for Legend Biotech's Cash from Financing Activities shows a peak YoY increase of 78,200.10% (in 2023) and a maximum YoY decrease of 1,876.00% (in 2023) over the last 5 years.
  • Over the past 5 years, Legend Biotech's Cash from Financing Activities (Quarterly) stood at $323.6 million in 2021, then crashed by 100.24% to -$783,000 in 2022, then spiked by 218.14% to $925,000 in 2023, then plummeted by 136.00% to -$333,000 in 2024, then slumped by 84.22% to $670,000 in 2025.
  • Its Cash from Financing Activities stands at $670,000 for Q3 2025, versus -$990,000 for Q2 2025 and $667,000 for Q1 2025.